HEMOPATIAS MALIGNAS - Instituto de Oncología Ángel H. Roffo

386 PAUTAS DE DIAGNOSTICO Y TRATAMIENTO / INSTITUTO ANGEL H. ROFFO
DTPACE (120)
DEXAMETASONA 40 mg/día VO Días 1 al 4
TALIDOMIDA 200 a 400 mg/día VO
CISPLATINO 10 mg/m 2 /día IV (inf cont) Días 1 al 4
DOXORRUBINA 10 mg/m 2 /día IV (inf cont) Días 1 al 4
CICLOFOSFAMIDA 400 mg/m 2 /día IV (inf cont) Días 1 al 4
ETOPOSIDO 40 mg/m 2 /día IV (inf cont) Días 1 al 4
Ciclos cada 4 a 6 semanas
CDEP
CICLOFOSFAMIDA 400 mg/m 2 /día IV (inf cont) Días 1 al 4
DEXAMETASONA 40 mg/día VO Días 1 al 4
ETOPOSIDO 40 mg/m 2 /día IV (inf cont) Días 1 al 4
CISPLATINO 10 mg/m 2 /día IV (inf cont) Días 1 al 4
BORTEZOMIB 1.3 mg/m 2 IV Días 1, 4, 8, 11
Ciclos 1 a 8. Cada 21 días
Definir respuesta para evaluar continuidad del tratamiento
Puede asociarse a DEXAMETASONA 40 mg/día Días 1 al 4
PAD
BORTEZOMIB 1.3 mg/m 2 IV Días 1, 4, 8, 11
DOXORRUBINA 9 mg/m 2 /día IV Días 1 al 4
DEXAMETASONA 40 mg/día VO Días 1 al 4, 8 al 11,
15 al 18 del ciclo 1
Días 1 al 4 de ciclos
2 a 4 ciclos cada 21 días
BIBLIOGRAFIA
105. Lacy M, et al. Mayo Clinic Consensus
Statement for the use of Bisphosphonates in
Multiple Myeloma. Mayo Clin Proc 2006; 81:
1047-1053.
106. Durie B, Kyle R, et al. Myeloma
management guidelines: a consensus report from
the Scientific Advisors of the International
Myeloma Foundation. The Hematology Journal
2003; 4: 379-398.
107. Barosi G, Boccadoro M, et al.
Management of multiple myeloma and related
disorders: guidelines from the Italian Society of
Hematology (SIE), Italian Society of Experimental
Hematology (SIES) and Italian Group for Bone
Marrow Transplantation (GITMO). Haematologica
2004; 89: 717-714.
108. Segeren C, Sonneveld P, et al. Vincristine,
doxorrubicin and dexametasone (VAD)
administered as rapid intravenous infusion for
first-line tretment in untreated multiple myeloma.
British Journal of Hematology 1999; 105: 127-
130.
109. Cavenagh J, Oakervee H. Thalidomide in
multiple myeloma: current status and future
prospects. British Journal of Hematology 2003;
120: 18-26.
110. Rajkumar V., Hayman S., Gertiz M, et al.
Combination therapy with thalidomida plus
dexamethasone for newly diagnosed myeloma.
Journal of Clin Oncol 2002; 20: 4319-4328.
111. Singhal S., Mehta J., Desikan R., et al.
Antitumor activity of thalidomide in refractory
multiple myeloma. New Eng J Med 1999; 341:
1565-1571.
112. Richardson P., Barlogie B, Berenson J., et
al. A phase 2 study of bortezomib in relapsed
refractory myeloma. New Eng J Med 2003; 348:
2609-2617.
113. Kyle R. Hematopoietic cell transplantation
in multiple myeloma. Up To Date 2004, vol 12, n 2
114. Attal M, Harpisseau J., Stoppa A, et al.
A prospective randomized trial of autologous
bone marrow transplantation and chemotherapy
in multiple myeloma. Intergroupe Francais du
Myelome. N Eng J Med 1996; 335: 1844-1845.
115. Child J, Morgan G, Davies F, et al. High
dose chemotherapy with hematopoietic stem
cell rescue for multiple myeloma. N Eng J Med
2003; 348: 1875-1883.
116. Barlogie B, Jagannath S, Desikan K, et al.
Total therapy with tandem transplant for newly
diagnosed multiple myeloma. Blood 1999; 93:
55-65.
117. Attal M, Harousseau J, Facon T et al.
Single versus double autologous stem cell
transplantation for multiple myeloma. N Eng J
Med 2003 ; 349 : 2495-2502.